Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21315834 | 1.00 | TSHR (0.38) | TSHRPOLBRENKMT2AALDH1A1 | |
| SCHEMBL21315838 | 1.00 | TSHR (0.38) | TSHRPOLBRENKMT2AALDH1A1 | |
| SCHEMBL20141289 | 0.85 | REN (0.42) | RENKMT2ALMNA | |
| SCHEMBL900236 | 0.85 | REN (0.42) | RENKMT2ALMNA | |
| SCHEMBL28879462 | 0.82 | ALDH1A1 (0.39) | TSHRPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL29713922 | 0.82 | ALDH1A1 (0.39) | TSHRPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL21315839 | 0.82 | ALDH1A1 (0.39) | TSHRPOLBKMT2AALDH1A1MAPT | |
| SCHEMBL2919417 | 0.82 | POLB (0.39) | TSHRPOLBKMT2AALDH1A1LMNA | |
| SCHEMBL16178360 | 0.79 | PARP1 (0.43) | RENMAPT | |
| SCHEMBL18788447 | 0.79 | PARP1 (0.43) | RENMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2023-09-07 | — | — | US | disclosed |
| WO-2022166749-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海湃隆生物科技有限公司 | 2022-08-11 | — | — | WO | disclosed |
| EP-3532062-B1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES BV (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-06-09 | — | — | US | disclosed |
| US-20210069182-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-03-11 | — | — | US | disclosed |
| US-10905687-B2 | Substituted piperazines as ROR-gamma modulators | ESCALIER BIOSCIENCES B.V. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190269674-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES, BV (US) | 2019-09-05 | — | — | US | disclosed |
| US-7534887-B2 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070010528-A1 | Thiazoline derivative and use of the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1669352-A1 | THIAZOLINE DERIVATIVE AND USE OF THE SAME | Takeda Pharmaceutical Company Limited (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010528-A1 | Thiazoline derivative and use of the same | TBXA2R, F2, F3 | TSHR 12/4885POLB 3180/4885REN 1269/4885 |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | TSHR 588/4885POLB 2301/4885REN 2718/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | TSHR 588/4885POLB 2301/4885REN 2718/4885 |
| US-20210069182-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | TSHR 588/4885POLB 2301/4885REN 2718/4885 |
| US-10905687-B2 | Substituted piperazines as ROR-gamma modulators | RORC, RORA, RORB | TSHR 544/4885POLB 1965/4885REN 1400/4885 |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | TSHR 588/4885POLB 2301/4885REN 2718/4885 |
| US-20190269674-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | TSHR 588/4885POLB 2301/4885REN 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.